CD38 and Miyoshi myopathy: A landmark 2019 multi-institution study showed that patients with penta-refractory MM (defined as refractory to an anti-CD38 mAb, two proteasome inhibitors, and two Ikaros degraders) survived a median of only 5.6 months (Gandhi et al. 2019).